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Telomere length (TL) has been associated with outcome in
chronic lymphocytic leukemia (CLL). The aim of this extensive
analysis carried out on 401 CLL patients was to assess TL
conclusively as a prognostic biomarker. Our study included
two cohorts used as learning (191 patients) and blinded
validation series (210 patients). A TL cutoff of 5000 bp was
chosen by receiver operating characteristic (ROC) analysis and
Youden’s index in the learning series. In this series,
TLp5000 bp was independently associated to a worse outcome
for both overall survival (OS; 105.5 vs 281 months, Po0.001)
and treatment-free survival (TFS; 24.6 vs 73 months, Po0.001).
In the blinded validation series, TLp5000 bp was confirmed as
an independent outcome predictor for OS (79.8 vs not reached,
Po0.001) and TFS (15.2 vs 130.8 months, Po0.001). Moreover,
TLp5000 bp independently predicted the risk of Richter’s
syndrome (5-year risk: 18.9 vs 6.4%, P¼0.016). Within CLL
subsets defined by biological predictors, TL consistently
identified patient subgroups harboring unfavorable prognosis.
These results demonstrate that TL is a powerful independent
predictor of multiple outcomes in CLL, and contributes to refine
the prognostic assessment of this disease when utilized in
combination with other prognostic markers. We thus believe
that this prognostic biomarker has the potential for a more
widespread use in CLL.
Leukemia (2009) 23, 1062–1072; doi:10.1038/leu.2008.399;
published online 2 April 2009
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Introduction
Chronic lymphocytic leukemia (CLL) has a highly hetero-
geneous clinical course: some patients have a normal or nearly
normal life expectancy, whereas others shortly succumb to their
disease.1–4 In recent years, several biomarkers have been used
for outcome prediction in this neoplasm. Currently, the most
widely used biomarkers are cytogenetics, immunoglobulin
heavy-chain variable gene mutation status (IGHV-MS) and
expression of ZAP70 and CD38.4–14 Despite the established
prognostic value of these biomarkers, a stratification according
to these parameters does not fully explain the heterogeneity of
CLL. In addition, scant information is available on independent
predictors of some critical events in CLL, such as clinicopatho-
logical transformation to aggressive lymphoma, also known as
Richter’s syndrome (RS).15 Thus, further improvement of our
current predictive tools would be advisable.
Telomeres are complex structures composed of repeated
nucleotide sequences and by a number of proteins having both
structural and regulatory functions. Telomeres have a major
function ensuring genetic stability and regulating critical cellular
functions, including proliferation and replicative senescence.16–18
Several lines of evidence suggest that cancer cells have
dysfunctional telomeres, often characterized by marked short-
ening of the DNA component and upregulation of telomerase,
possibly aimed at stabilizing critically shortened telomeric
sequences.19–22 Telomeric dysfunction has been recently docu-
mented to be a prominent feature of CLL cells, which are
characterized by major defects of telomere-related proteins.23
On the basis of these considerations, it is not surprising that
telomere-related parameters are linked to outcome in CLL.
A number of reports have shown that short telomeres and
expression of h-tert, the catalytic subunit of telomerase, are poor
prognostic factors in this neoplasm.24–27 Although early studies
postulated that telomere length (TL) was mostly acting as a
surrogate marker for IGHV-MS, a number of subsequent reports
indicated that in discordant cases TL performed better than
IGHV-MS, suggesting that TL deserved further consideration as a
prognostic biomarker in CLL.28,29
Despite these encouraging results, additional experience
needs to be accumulated on TL as a prognostic marker in CLL.
First, a larger patient sample is required to establish the
prognostic role of TL fully, define the optimal cutoff value and
confirm results in a blinded validation series. Second, the
independent prognostic value of TL needs to be proven by
multivariate Cox regression analysis not only for treatment-free
survival (TFS), but also for overall survival (OS). Finally, the
prognostic value of TL should be tested in the context of well-
established CLL prognostic subgroups, to understand the
outcome of cases with discordance between TL and other CLL
predictors. These issues have been addressed on a CLL learning
cohort and validated on an independent blinded cohort, overall
accounting for 401 CLL patients. Also, we have tested TL as a
risk factor of RS, an extremely severe event that most of the
currently available biomarkers fail to predict.15,30
Patients and methods
Patient population and development of a blinded
validation series
The patient sample of this study consisted of two large
consecutive CLL cohorts (Table 1). The first cohort belonged
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to the Division of Hematology of the University of Turin (UT;
n¼ 191) and was used as learning series. The second cohort
belonged to the Division of Hematology of the Amedeo
Avogadro University of Eastern Piedmont (AAUEP; n¼ 210)
and was used as blinded validation series. Both series were
updated for the analysis in February 2008. All patients provided
informed consent in accordance with local institutional review
board requirements and the Declaration of Helsinki Principles.
In both series, diagnosis of CLL was based on National Cancer
Institute (NCI) Working Group criteria and confirmed by a flow
cytometry score 43 in all cases.31,32 Also, in both series,
patients were managed according to NCI Working Group
guidelines.32
Median follow-up of patients from the UT learning series was
32 months. The following demographic and clinical variables
were recorded for patients included in the UT learning series:
date of diagnosis, age, sex, Binet stage, date of first-line
treatment and date of death. The following biological variables
were available for the UT learning series: TL, IGHV gene usage,
homology to germ-line IGHV sequences (IGHV-MS) and
presence of a complementarity-determining region (CDR) 3
belonging to published subsets of stereotyped B-cell receptors
(BCR),33 fluorescence in situ hybridization (FISH) karyotype for
del(13q14), þ 12, del(17p13), del11(q22–q23), CD38 and
ZAP70 expression.
Median follow-up of patients from the AAUEP blinded
validation series was 54.2 months. The following demographic
and clinical variables were recorded at presentation for patients
included in the AAUEP validation series: date of diagnosis, age,
sex, ECOG performance status, Rai stage, Binet stage, spleen
size (cm below left costal margin), size of largest node (cm of the
largest transversal diameter), lymphocyte count, hemoglobin,
platelet count, serum b-2-microglobulin (normal range
1.8–2.3 mg/100 ml), lactate dehydrogenase (LDH, normal range
200–450 U/l), alkaline phosphatase (normal range 90–360 U/l),
albumin (normal range 34–48 g/l), immunoglobulin levels
(normal ranges IgG 7–16 g/l, IgA 0.7–4 g/l, IgM 0.4–2.3 g/l),
CD4þ lymphocyte count, presence of monoclonal component,
direct antiglobulin test, percentage of bone marrow lympho-
cytes, pattern of infiltration (diffuse vs non-diffuse) on bone
marrow biopsy, date of first-line treatment according to NCI
Working Group guidelines,32 date of lymphocyte doubling, date
of progression to a more advanced stage, date of transformation
to RS (based on histology of lymph node or extranodal tissue
biopsy in accordance to the World Health Organization
Classification of Tumors of the Haematopoietic and Lymphoid
Tissues)34 and date of death. The following biological variables
were available for the AAUEP validation series: TL, IGHV gene
usage, homology to germ-line IGHV sequences (IGHV-MS) and
presence of CDR3 belonging to published subsets of stereotyped
BCR,33 FISH karyotype for del(13q14), þ 12, del(17p13),
del11(q22–q23), CD38 and ZAP70 expression.
All biological variables collected for both series were
analyzed on fresh or cryopreserved peripheral blood mono-
nuclear cells at the time of CLL diagnosis.
Normal B cells from a panel of 30 age-matched controls were
used to compare TL of CLL versus normal cells.
Determination of TL
Peak TL was determined for the whole series by Southern blot
analysis as reported elsewhere.29,35 Peak TL was preferred to
Table 1 Biological and clinical characteristics of the learning CLL series from the UT (n¼191) and the validation CLL series from the AAUEP
(n¼210)
Characteristics at CLL diagnosis University of Turin Amedeo Avogadro University P
Age (years)a 61 53–69 69 62–76 o0.001
Male 118/191 61.8% 118/210 56.2% 0.256
Binet stage
A 129/191 67.5% 154/210 73.3% 0.437
B 31/191 16.2% 29/210 13.8%
C 31/191 16.2% 27/210 12.9%
Nodal areas X3 NA NA 37/210 17.6% NA
Largest lymph node X3 cm NA NA 29/210 13.8% NA
Splenomegaly NA NA 41/210 19.5% NA
Peripheral blood lymphocytes ( 109 per liter) NA NA 11.7 6.3–20.0 NA
Hb (g/100 ml) NA NA 13.5 12.3–14.6 NA
Platelets (109 per liter) NA NA 190 140–226 NA
Bone marrow lymphocytes (%) NA NA 40 25–70 NA
Diffuse bone marrow pattern NA NA 48/207 23.2% NA
b-2-Microglobulin (mg/l) NA NA 2.5 1.8–3.5 NA
LDH (U/l) NA NA 350 296–430 NA
Alkaline phosphatase (U/l) NA NA 155 126–180 NA
Albumin (g/l) NA NA 42 39–45 NA
IGHV homology X98% 78/191 40.8% 75/208 36.1% 0.327
FISH stratification
del(13q14)/normal/+12 107/131 81.7% 164/201 82.0% 0.941
del(1q22–q23)/del(17p13) 24/131 18.3% 37/201 18.0%
Number of FISH lesions 41 16/131 12.2% 37/201 18.4% 0.157
CD38 X30% 59/150 39.3% 65/209 31.1% 0.106
ZAP70 X20% 43/106 40.6% 54/177 30.5% 0.084
Telomere length (bp)a 6024 4566–7688 5959 4667–7002 0.343
Telomere length p5000 bp 61/191 31.9% 62/210 29.5% 0.601
Abbreviations: CLL, chronic lymphocytic leukemia; FISH, fluorescence in situ hybridization; LDH, lactate dehydrogenase.
aMedian and 25th–75th percentiles are reported for continuous variables.
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mean TL because this approach allows accurate measurement of
TL in the presence of up to 30% contaminating non-neoplastic
cells, as documented by extensive cell dilution studies.35 Briefly,
2 mg of genomic DNA was digested by mixing HinfI and RsaI
(Roche Diagnostics, Mannheim, Germany). Telomere restriction
fragments were separated by 0.8% agarose gel electrophoresis.
Gels were transferred to a positively charged nylon membrane
(Roche Diagnostics) and were UV cross-linked. Hybridization
and detection were performed using the TeloTAGGG Telomere
Length Assay Kit (Roche Diagnostics), as previously described.35
Membranes were scanned and analyzed with Kodak Digital
Science 1D software (Scientific Imaging Systems, New Haven,
CT, USA).
Data on TL were not available to clinicians and did not affect
their therapeutic decisions. Because TL analysis was performed
at UT, the AAUEP series was used as a blinded validation
sample. All DNAs from the AAUEP series were anonymously
sent to UT, without any information on clinical and biological
features. The results were then sent back to AAUEP, where the
final outcome analysis was performed.
IGVH analysis
Tumor-specific IGHV rearrangements were amplified starting
from genomic DNA as described elsewhere.29 IGHV sequences
were aligned to ImMunoGeneTics directories (www.imgt.
cines.fr), and considered mutated if homology to the corres-
ponding germ-line gene was o98%. HCDR3-driven clustering
was performed by converting all in-frame IGHV rearrangements
into amino-acid sequences, and by aligning HCDR3 sequences
by means of the multiple sequence alignment software ClustalW
(www.ebi.ac.uk/clustalw/; EMBL-EBI, European Bioinformatics
Institute).36
CD38 and ZAP70 expression by flow cytometry
A FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA,
USA) was used for flow cytometric analysis. Expression of CD38
and ZAP70 was analyzed as reported.6,8,9 Cutoff points of 30
and 20% were used to define positivity for CD38 and ZAP70,
respectively.
FISH analysis of chromosomal imbalances
Dual-color interphase FISH for del(13q14), þ 12, del(11q22–
q23) and del(17p13) was performed using standard protocols.
Briefly, probes (Vysis, London, UK) used for FISH analysis
were: LSI13 and LSID13S319 for detection of del(13q14); CEP12
for detection of aneuploidy of chromosome 12; LSIp53 for
detection of del(17p13) and LSIATM for detection of del(11q22–
q23). Patients were classified as having del(13q14), þ 12,
del(11q22–q23), del(17p13) and normal karyotype, according to
the hierarchical stratification model proposed by Do¨hner et al.5
Clinicians were aware of the FISH status of their patients and, for
patients with NCI indications to treatment, this knowledge might
have affected the choice of the therapeutic regimen adopted.
Statistical analysis
The series from UT was used as learning cohort in whom
investigations aimed at (1) defining the best cutoff for TL and (2)
testing TL at the selected cutoff as an independent prognos-
ticator for OS and TFS of CLL. The series from AAUEP was used
as validation cohort in whom investigations aimed at (1)
confirming TL at the selected cutoff as an independent
prognosticator for OS and TFS, (2) testing TL at the selected
cutoff as an independent predictor of RS transformation.
The cutoff point for TL was selected according to receiver
operating characteristic (ROC) analysis using death as state
variable, and Youden’s index calculated utilizing the sensitivity
and specificity derived from ROC analysis.
Overall survival was measured from the date of CLL diagnosis
to the date of last follow-up or death. TFS was measured from
diagnosis to first-line treatment, death or last follow-up. All
patients underwent first treatment at the time of documentation
of progressive and symptomatic disease according to NCI
Working Group guidelines.32 Time to lymphocyte doubling
was measured from diagnosis to lymphocyte doubling, death or
last follow-up. As previously reported,8 time to progression to a
more advanced stage was defined as the time elapsed from
diagnosis to progression to a more advance stage, first-line
treatment according to NCI Working Group guidelines, death or
last follow-up. Date of transformation was defined as the date of
the biopsy showing that RS transformation occurred. Time to RS
transformation was measured from date of CLL diagnosis to date
of transformation, death or last follow-up.
Categorical variables were compared by w2-test and Fisher’s
exact test when appropriate. Continuous variables were
compared by Mann–Whitney test. Survival analysis was
performed by Kaplan–Meier method, using log-rank statistics
to test for significant associations.37 Cox proportional hazard
regression was used to build a multivariate model.38
Stratification of continuous clinical variables was based on
the best predictive cutoff value or usual limit of normal. All
statistical tests were two sided. Statistical significance was
defined as P-valueo0.05. The analysis was performed with the
Statistical Package for the Social Sciences (SPSS) software
version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
Identification of the best TL cutoff for prediction of TFS
and OS in CLL
Median TL of the CLL patients in the learning series was 6311 bp
and was similar to that reported in other CLL series.25,39 The
median TL observed in the CLL learning series was significantly
lower compared to the median TL observed in normal B cells,
which showed a median TL of 7396 bp (Po0.001; data not
shown) in CLL cells was not associated with age or sex (data not
shown; P¼ 0.20 and 0.161, respectively). The best TL cutoff
point was generated in the learning CLL series from UT (n¼ 191)
by ROC analysis and Youden’s index using death as state
variable. Accordingly, the best cutoff point for TL was 5000 bp
(Supplementary Figure 1S). On the basis of selected cutoff, 61/
191 (31.9%) CLL patients of the learning series harbored
TLp5000 bp. Because a sizeable fraction of cases in the
learning cohort lacked data on FISH karyotype (60/191,
31.4%), and expression of CD38 (41/191, 21.4%) and ZAP70
(85/191, 44.5%), these variables were not included in the
univariate and multivariate models applied to the learning
series.
After a median follow-up of 32 months from diagnosis, 90/
191 patients of the learning series had progressed to sympto-
matic disease requiring treatment according to NCI Working
Group guidelines. Median TFS was 49.8 months (95% CI 31.9–
67.6). Univariate analysis identified TLp5000 bp as a predictor
of reduced TFS (TLp5000 bp: 24.6 months vs TL 45000 bp:
73.0 months; P¼ 0.001) (Figure 1a; Supplementary Table 1S).
Other predictors of reduced TFS by univariate analysis were
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advanced Binet stage and IGHV homologyX98% (Supplemen-
tary Table 1S) (Po0.05 in all instances). Multivariate analysis
selected TLp5000 bp (hazard ratio (HR) 1.77; 95% CI
1.16–2.69; P¼ 0.008) as an independent predictor of reduced
TFS along with advanced Binet stage (HR 3.97; 95% CI 2.57–
6.13; Po0.001). Advanced Binet stage at diagnosis may be
per se an indication to first-line treatment. Therefore, multi-
variate analysis for TFS was also assessed after removing Binet
B-C stage from covariates. TLp5000 bp was selected in this
model as the sole independent predictor of reduced TFS (HR
2.02; P¼ 0.001; Table 2).
After a median follow-up of 32 months from diagnosis,
20/191 patients of the learning series died. Median OS was
269.3 months (95% CI 212.2–337.4). According to univariate
analysis, TLp5000 bp was associated with poor OS
(TLp5000 bp: 105.5 months vs TL45000 bp: 281.0 months;
Po0.001) (Figure 1b; Supplementary Table 2S). Other variables
predicting reduced OS by univariate analysis were advanced
Binet stage and IGHV homology X98% (Po0.05 in all
instances; Supplementary Table 2S). Multivariate analysis
identified TLp5000 bp (HR 13.31; Po0.001) as an independent
predictor of reduced OS along with advanced Binet stage (HR
5.34; P¼ 0.002; Table 2).
Validation of short TL at the cutoff of 5000 bp as an
independent predictor of progressive CLL according
to NCI criteria
The prognostic value of short TL at the cutoff of p5000 bp as a
predictor of TFS was validated in the independent CLL series
(n¼ 210) from AAUEP. When comparing clinical and biological
features of the learning and validation series, the two series were
similar in terms of TL, Binet stage distribution and prevalence of
unfavorable biological prognosticators (Table 1). The only
significant difference between the two series was patient median
age (Po0.001; Table 1). Again, also in the AAUEP validation
series, TL in CLL cells was not associated with age or sex (data
not shown; P¼ 0.28 and 0.24, respectively). The AAUEP
validation series was provided with additional variables at
diagnosis that were not available for the learning series. Also,
only a low number of cases in the validation series lacked data
on FISH karyotype (9/210, 4.2%), CD38 (1/210, 0.4%) and
ZAP70 (33/210, 15.7%) expression (Table 1). All these
parameters were thus included in univariate and multivariate
analyses for this series.
On the basis of selected cutoff, 62/210 (29.5%) CLL patients
of the validation series harbored TLp5000 bp. After a median
follow-up of 54.2 months from diagnosis, 95/210 patients
progressed to symptomatic disease requiring treatment accord-
ing to NCI guidelines. Median TFS was 67.4 months (95%
CI 37.0–97.8). Univariate analysis identified TLp5000 bp as a
predictor of reduced TFS (TLp5000 bp: 15.2 months vs
TL45000 bp: 130.8 months; Po0.001; Figure 2a). Other
predictors of reduced TFS by univariate analysis are listed in
Supplementary Table 3S (Po0.05 in all instances). Multivariate
analysis selected TLp5000 bp (HR 1.85; 95% CI 1.13–3.03;
P¼ 0.013) as an independent predictor of reduced TFS, along
with advanced Binet stage (HR 6.19; 95% CI 3.55–10.79;
Po0.001), peripheral blood lymphocytes (HR 3.10; 95% CI
1.87–5.12; Po0.001), CD38 expression (HR 2.76; 95% CI
1.65–4.60; Po0.001) and b-2-microglobulin levels (HR 2.22;
95% CI 1.30–3.79; P¼ 0.003).
For the reasons already outlined for the learning series,
multivariate analysis for TFS in the validation series was also
assessed after removing Binet B-C stage from covariates. This
analysis confirmed TLp5000 bp as an independent predictor of
reduced TFS (HR 2.14; P¼ 0.002) along with peripheral blood
lymphocytes (HR 3.27; Po0.001), CD38 expression (HR 2.68;
Po0.001), b-2-microglobulin levels (HR 2.53; P¼ 0.001) and
unfavorable FISH karyotype (HR 1.72; P¼ 0.046) (Table 2).
Short TL at the cutoff of 5000 bp associates with markers
of proliferation and rapid kinetics of CLL
At CLL diagnosis, TLp5000 bp was associated with clinical
markers of leukemic disease, such as Binet C stage (P¼ 0.020),
lymphocyte count (Po0.001), bone marrow pattern (o0.001)
and extent of infiltration (Po0.001), anemia (Po0.001) and
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Figure 1 Performance of telomere length (TL) in the UT learning series. TL is predictive of treatment-free survival (TFS; a) and overall survival
(OS; b) in the UT learning series of 191 patients.
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splenomegaly (P¼ 0.003) (Supplementary Table 4S; Figure 3).
Moreover, at CLL diagnosis, TLp5000 bp was associated with
clinical markers of proliferation, such as LDH (P¼ 0.010) and
b-2-microglobulin levels (P¼ 0.015). On the contrary,
TLp5000 bp was not associated with clinical markers of solid
disease, such as Binet B stage, lymph node size (P¼ 0.285) or
extent of nodal involvement (P¼ 0.222). Among biological
variables at diagnosis, TLp5000 bp was associated with IGHV
homology X98% (Po0.001), unfavorable FISH karyotype
(Po0.001), complex FISH karyotype as depicted by higher
number of FISH lesions (P¼ 0.018) and expression of CD38
(Po0.001) and ZAP70 (P¼ 0.038).
The association between TLp5000 bp and markers of
proliferation prompted investigations on the impact of
TLp5000 bp on disease kinetics. TFS was used as the primary
end point of progressive disease according to NCI criteria (see
above). We also reasoned that TFS may not capture all events
relevant to CLL kinetics, such as lymphocyte doubling and
progression to a more advanced stage, because a fraction of
these events does not meet NCI criteria for progressive disease
requiring treatment. Therefore, lymphocyte doubling and time
to progression to a more advanced stage were used as additional
end points of disease kinetics. Univariate log-rank analysis
identified TLp5000 bp as a risk factor of reduced time to
lymphocyte doubling and of reduced time to progression to a
more advanced stage (Figures 2b and c). Median time to
lymphocyte doubling for patients with TLp5000 bp was 10.5
months (95% CI 5.5–15.5) compared to 41.4 months (95% CI
30.8–51.9) for patients with TL45000 bp (Po0.001). Also,
median time to progression to a more advanced stage for
patients with TLp5000 bp was 10.5 months (95% CI 5.3–15.8),
compared to 49.8 months (95% CI 32.9–66.6) for patients with
TL45000 bp (Po0.001).
Validation of short TL at the cutoff of 5000 bp as an
independent predictor of overall survival in CLL
The prognostic value of short TL at the cutoff of p5000 bp as a
predictor of OS was validated in the independent series
(n¼ 210) from AAUEP. At the time of the analysis, 51/210
patients of the validation series had died and median OS was
144 months (95% CI 107.6–180.4). According to univariate
analysis, TLp5000 bp was associated with poor OS
(TLp5000 bp: 79.8 months vs TL45000 bp: not reached;
Po0.001; Figure 2d). Other variables predicting reduced OS
by univariate analysis were age, Binet stage, b-2-microglobulin
levels, unfavorable FISH karyotype and ZAP70 expression
(Po0.05 in all instances; Supplementary Table 5S). Multivariate
analysis identified TLp5000 bp (HR 1.91; P¼ 0.035) as an
independent predictor of reduced OS along with age 465 years
(HR 4.02; Po0.001) and advanced Binet stage (HR 2.14;
P¼ 0.015) (Table 2).
TL is an independent predictor of Richter’s syndrome
transformation
The AAUEP CLL series (n¼ 210) was managed according to a
uniform biopsy policy for detection of RS transformation.15
Accordingly, 17/210 CLL patients had transformed to RS,
accounting for a 5-year cumulative risk of transformation of
Table 2 Multivariate analysis for OS, TFS, RS transformation and recurrent infections
HR 95% CI P
TFS UTa
Telomere length p5000 bp 2.02 1.33–3.07 0.001
TFS AAUEPb
Peripheral blood lymphocytes 420 109 per liter 3.27 1.97–5.42 o0.001
CD38 X30% 2.68 1.64–4.39 o0.001
b-2-Microglobulin 42.5 mg/l 2.53 1.49–4.29 0.001
del(11q22–q23)/del(17p13) 1.72 1.01–2.95 0.046
Telomere length p5000 bp 2.14 1.32–3.47 0.002
OS UTc
Binet B-C 5.34 1.85–15.41 0.002
Telomere length p5000 bp 13.31 3.76–47.05 o0.001
OS AAUEPd
Age 465 years 4.02 1.85–8.74 o0.001
Binet B-C 2.14 1.15–3.96 0.015
Telomere length p5000 bp 1.91 1.04–3.52 0.035
RS transformation AAUEP e
Largest lymph node X3 cm 7.46 2.65–20.96 o0.001
No del13q14 4.18 1.15–15.14 0.029
Telomere length p5000 bp 2.70 1.04–7.40 0.048
Abbreviations: AAUEP, Amedeo Avogadro University of Eastern Piedmont; HR, hazard ratio; 95% CI, 95% confidence interval; OS, overall survival;
P, P-value calculated by Cox analysis; RS, Richter’s syndrome; TFS, treatment-free survival; UT, University of Turin.
Only significant covariates for each outcome are listed above.
aCovariates that entered the analysis were telomere length, IGHV gene homology, age, sex and Binet stage.
bCovariates that entered the analysis were telomere length, IGHV gene homology, unfavorable FISH karyotype, CD38 expression, ZAP70
expression, Binet stage, peripheral blood lymphocytes and b-2-microglobulin levels.
cCovariates that entered the analysis were telomere length, IGHV gene homology and Binet stage.
dCovariates that entered the analysis were telomere length, IGHV gene homology, unfavorable FISH karyotype, age, Binet stage and b-2-
microglobulin levels.
eCovariates that entered the analysis were telomere length, del(13q14) and large lymph node size.
Telomeres in chronic lymphocytic leukemia
D Rossi et al
1066
Leukemia
10.0% (95% CI 5.0–15.0%). This allowed the assessment of
short TL at the cutoff of p5000 bp as a predictor of RS
transformation. By univariate analysis, TLp5000 bp was asso-
ciated with an increased risk of RS (5-year risk for TLp5000 bp:
18.9% vs 5-year risk for TL45000 bp: 6.4%; P¼ 0.016)
(Supplementary Table 6S; Figure 4). Large lymph node size
and absence of del(13q14) at diagnosis have been previously
identified as independent predictors of RS transformation in the
P
B
 ly
m
p
h
o
cy
te
s 
(x
10
9 /
l)
100
90
80
70
60
50
40
30
20
10
B
M
 ly
m
p
h
o
cy
te
s 
(%
)
H
b
 (
g
/d
l)
90
80
70
60
50
40
30
20
10
TL>5000 bp TL≤5000 bpTL>5000 bp
100%
75%
50%
25%
0%
100%
75%
50%
25%
0%
100%
75%
50%
25%
0%
100%
75%
50%
25%
0%
100%
75%
50%
25%
0%
100%
75%
50%
25%
0%
100%
75%
50%
25%
0%
100%
75%
50%
25%
0%
A B C
Binet stage
No Yes
Splenomegaly
Non-diffuse Diffuse
Bone marrow pattern
<20% ≥20%
ZAP70 expression
<30% ≥30%
CD38 expression
<98% ≥98%
IGHV homology
del17 del11 +12 normal del13
FISH karyotype
≤1 >1
Number of FISH lesions
Telomere length
>5000 bp
<5000 bp
Telomere length
>5000 bp
<5000 bp
Telomere length
>5000 bp
<5000 bp
Telomere length
>5000 bp
<5000 bp
Telomere length
>5000 bp
<5000 bp
Telomere length
>5000 bp 
<5000 bp
Telomere length
>5000 bp
<5000 bp
Telomere length
>5000 bp
<5000 bp
TL≤5000 bp
TL>5000 bp TL≤5000 bp TL>5000 bp TL≤5000 bp TL>5000 bp TL≤5000 bp
200
300
400
500
600
700
L
D
H
 (
U
/I)
5.0
4.0
3.0
2.0
1.0
6.0
B
et
a-
2-
m
ic
ro
g
lo
b
u
lin
 (
m
g
/l)
10
17
16
15
14
13
12
11
9
8
Figure 2 Performance of telomere length (TL) in the AAUEP blinded validation series. TL is predictive of treatment-free survival (TFS; a), time to
lymphocyte doubling (b).
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AAUEP series.15 On these bases, lymph node size and
del(13q14) entered multivariate analysis along with TL.15
Multivariate analysis selected TLp5000 bp as an independent
predictor of RS transformation (HR 2.70; P¼ 0.048), along with
lymph node size (HR 7.46; Po0.001) and absence of del(13q14)
(HR 4.18; P¼ 0.029) (Table 2).
TL refines the prognostication of CLL subgroups
identified by conventional CLL risk factors
The learning and the validation series were combined into a
single group of CLL patients (n¼ 401) for further detailed
analysis of the interactions between TL and other CLL risk
factors. Of note, a consistent proportion of patients showed a
short TL in the presence of favorable prognosticators, and vice
versa. These cases were defined as discordant and accounted for
147/401 (36.6%) patients for TL vs Binet stage, 105/399 (26.3%)
for TL versus IGHV-MS, 103/331 (31.1%) for TL vs cytogenetics,
108/283 (38.1%) for TL versus ZAP70 expression and 130/359
(36.2%) for TL versus CD38 expression. Short TL in our series
identified a CLL subgroup that displayed rapid disease progres-
sion and reduced survival despite being characterized
at diagnosis by favorable predictors. This observation is
reproducible in all favorable risk categories.
In the whole CLL series, reduced TFS was predicted by
TLp5000 bp (Po0.001) along with advanced Binet stage
(Po0.001), IGHV homology X98% (Po0.001), unfavorable
FISH (Po0.001), CD38 (Po0.001) and ZAP70 (P¼ 0.001)
expression. Interaction analysis showed that TLp5000 bp
segregated a group of CLL displaying reduced TFS despite being
characterized by Binet stage A (Po0.001), IGHV homology
o98% (Po0.001), favorable FISH karyotype (Po0.001), CD38
o30% (Po0.001) or ZAP70 o20% (Po0.001) (Supplementary
Table 7S; Figures 5a–c).
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In the whole CLL series, reduced OS was predicted by
TLp5000 bp (Po0.001) along with age 465 years (Po0.001),
advanced Binet stage (Po0.001), IGHV homology X98%
(P¼ 0.001) and unfavorable FISH karyotype (P¼ 0.001).
Regarding OS, TLp5000 bp segregated a group of CLL
displaying reduced OS despite being characterized by
age p65 years (Po0.001), Binet stage A (P¼ 0.001) or
IGHV homology o98% (Po0.001) (Supplementary Table 8S;
Figures 5d–f). Also, among CLL patients carrying unfavorable
prognosticators, TL45000 bp identified a CLL subgroup dis-
playing longer OS despite being characterized by age 465
years (P¼ 0.004), Binet stage B-C (Po0.001) or unfavorable
cytogenetics (P¼ 0.001) (Supplementary Table 8S; Figures 5d–f).
TL in CLL with and without stereotyped B-cell receptors
We tested whether TL differed in CLL with and without a
stereotyped BCR. Our series included 89/336 (26.5%) evaluable
patients who showed a stereotyped BCR.36 Patients with a
stereotyped BCR carried a shorter TL (TLp5000 bp: 42/89,
47.7%) compared to patients without stereotyped BCR
(TLp5000 bp: 56/247, 27.1%) (P¼ 0.001). No differences were
found by comparing stereotyped and nonstereotyped CLL in the
context of IGHV-mutated or -unmutated CLL (P40.05 for all
comparisons), suggesting that TL differences between stereo-
typed and nonstereotyped cases should be ascribed to IGHV-
MS. The patient sample was not large enough to allow a
correlation of TL with specific stereotyped BCR clusters
considered independently.
Discussion
We report the largest available analysis of the prognostic role of
TL in CLL. The prognostic impact of TL and optimal choice of
cutoff value have been investigated on a learning series, and
validated on an independent blinded series. Our results show
that (1) 5000 bp is the best cutoff point for the definition of short
TL; (2) short TL associates with markers of proliferation and rapid
disease kinetics; (3) short TL is an independent predictor of all
CLL outcomes including TFS, OS and RS transformation and (4)
TL contributes to refine the prognostic assessment of CLL when
used in combination with other prognostic markers.
Short TL is a prominent feature of several neoplasms and has
been linked to outcome in several cancer types.40–44 Short
telomeres are not only a by-product of tumor development. In
fact, telomeric loss could be instrumental in maximizing the
malignant potential of tumor cells by boosting genetic instability
and by interfering epigenetically with genes located in sub-
telomeric regions.22,45,46 Also, the effort of preserving telomeres
from critical shortening can lead to upregulation of telomerase
and deregulation of other telomere-related proteins that might
contribute to neoplastic growth by multiple mechanisms.22
On the basis of these premises, it is not surprising that TL
bears independent prognostic value in CLL.28,29 Previous studies
have shown that TL associates with IGHV homology, high-risk
cytogenetics and poor TFS.25,26 Subsequent reports outlined the
existence of patients in which discordance exists between TL
and IGHV-MS and suggested a superior predictive value of
TL.28,29 Finally, Roos et al.47 were able to link TL with poor
cytogenetics in a series of 152 patients, including samples
collected both at diagnosis and after treatment. Notably, the
independent effect of TL on OS was not demonstrated in any of
the previously published reports. Our report adds further
evidence for consideration, including the identification and
validation of a cutoff point for the definition of short TL, the
demonstration that TL predicts survival and RS transformation in
a manner that is independent of conventional clinical and
biological parameters, and the contribution of TL to refining CLL
prognostic categories.
Our strategy included the use of two institutional databases
(UT and AAUEP) used as learning and blinded validation series.
This two-step approach is considered optimal for successful
identification of powerful and reproducible prognostic markers
suitable for clinical use. This same validation procedure used for
TL is commonly used to corroborate clinically and/or biologi-
cally based prognostic indicators and has been used also in the
CLL field in a recent analysis comparing the relative value of
CD38, ZAP70 and VHMS.47–49
The identification and validation of a robust cutoff point is a
prerequisite for widespread application of any biomarker.
Previous studies in CLL used the median or the mean value of
TL, ranging from 4300 to 6000 bp among series, to perform
survival comparisons.24,25,28,47 With the aim of defining a highly
reproducible cutoff, we used a stringent statistical approach, that
is, ROC analysis and Youden’s index for cutoff identification,
followed by validation in an independent series. The 5000 bp
cutoff identified by this strategy was confirmed as an outcome
predictor in both series analyzed.
Short TL is an independent predictor of all major CLL
outcomes, including TFS, OS and transformation to RS, both
in the learning and in the validation series. A potential
explanation of the poor outcome characterizing CLL with short
TL may be derived from the rapid kinetics of progression
observed in this subgroup of patients, as documented by short
time to lymphocyte doubling and time to progression to a more
advanced stage. The association between TL and OS is of
particular relevance, as it is independent of all conventional CLL
predictors, either clinical or biological. The ability of predicting
RS transformation is another important feature of TL. RS is a
severe event occurring in 10–15% of CLL patients.15,50 Very few
studies have investigated the features that at CLL diagnosis may
Pr
o
ba
bi
lit
y 
of
 tr
an
sf
o
rm
at
io
n 
(%
)
100
80
60
40
20
0
months
0 24 48 72 96 120 144 168 192 216 240 264 288 312
p=0.016
TL >5000 bp
TL ≤5000 bp
AAUEP Events/N 5-year risk
TL >5000 bp 8/148 6.4%
TL ≤5000 bp 9/62 18.9%
Figure 4 Telomere length (TL) as a predictor for transformation to
Richter’s syndrome (RS). The 5-year cumulative risk of transformation
was 18.9% in patients with TLp5000 bp, as opposed to 6.4% for those
with long telomeres.
Telomeres in chronic lymphocytic leukemia
D Rossi et al
1069
Leukemia
herald the subsequent development of RS. Analysis of the risk of
RS transformation was allowed by the strict and uniform biopsy
policy adopted at AAUEP. This analysis shows that long
telomeres, along with del(13p14), are a major biological
protector against RS, further stressing the indolent nature of
CLL bearing TL45000 bp.
Given the increasing availability of biological CLL prognos-
ticators, novel molecular risk factors should provide information
that is useful for refining the prognostication of risk categories
identified by already existing markers. In the case of TL, the
relevance of this issue is documented by the frequency of
discordant cases (approximating 30%), exemplified by patients
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harboring short TL in the presence of a favorable asset of
conventional markers or vice versa. We have addressed the
issue of discordant cases by investigating interactions of TL with
conventional clinical and biological risk factors. Short TL in our
series identified a CLL subgroup that displayed rapid disease
progression and reduced survival despite being characterized at
diagnosis by favorable predictors, including IGHV homology,
FISH and Binet stage. Conversely, TL45000 bp softens the
unfavorable prognosis of patients with high-risk cytogenetics,
that is, del(11q22–q23) and del(17p13). Consistently, CLL
patients with del(11q22–q23) or del(17p13) but harboring a
TL45000 bp show an OS that is comparable to that of cases
without these cytogenetic abnormalities.
Although a large bulk of data on the prognostic role of TL at
diagnosis have been generated, a large longitudinal analysis of
TL at different time points is still lacking. Some preliminary
findings indicate that modest variations of TL exist over
prolonged periods of time, particularly in IGHV-unmutated
cases.25 However, given the long natural history of CLL, a large
patient series with a very prolonged follow-up is required for a
conclusive assessment of the potential interest for prognostic
discrimination of longitudinal variation of TL.
One potential drawback of TL is the presence of different
methods for the analysis. Previous studies have shown good
concordance between the approaches most commonly used, for
example, Southern blot and real-time PCR.28 Concordance of
results observed with different methods further adds to the
reliability and potential for wide applicability of TL analysis.28
Nevertheless, a multicenter standardization effort involving
multiple laboratories from different countries would be advi-
sable in the future for harmonization of TL studies. In particular,
a direct comparison between Southern blot, real-time PCR and
flow cytometry–FISH analyses would be advisable as well as a
careful analysis of factors that might generate intercenter
variability. Such efforts may be justified in view of the fact that
TL independently recapitulates all major CLL outcomes and, in
addition, adds novel prognostic information when used in
combination with existing biological markers.
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